Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies

• Published in: Journal of Alzheimer's disease Vol. 80; no. 4; p. 1603
• Main Authors: Gupta, Harsh V, Beach, Thomas G, Mehta, Shyamal H, Shill, Holly A, Driver-Dunckley, Erika, Sabbagh, Marwan N, Belden, Christine M, Liebsack, Carolyn, Dugger, Brittany N, Serrano, Geidy E, Sue, Lucia I, Siderowf, Andrew, Pontecorvo, Michael J, Mintun, Mark A, Joshi, Abhinay D, Adler, Charles H
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2021
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - pathology; Amyloid - metabolism; Aniline Compounds - adverse effects; Dopamine - metabolism; Ethylene Glycols - adverse effects; Fatal Outcome; Female; Fluorine Radioisotopes - adverse effects; Humans; Lewy Body Disease - diagnostic imaging; Lewy Body Disease - pathology; Male; Middle Aged; Plaque, Amyloid - diagnostic imaging; Positron-Emission Tomography - methods; Radiopharmaceuticals; Tetrabenazine - adverse effects; Tetrabenazine - analogs & derivatives; dementia with Lewy bodies; synucleinopathy; amyloid; Alzheimer’s disease; AV-133; VMAT2
• ISSN: 1875-8908
• DOI: 10.3233/JAD-200323

Imaging biomarkers have the potential to distinguish between different brain pathologies based on the type of ligand used with PET. AV-45 PET (florbetapir, Amyvid™) is selective for the neuritic plaque amyloid of Alzheimer's disease (AD), while AV-133 PET (florbenazine) is selective for VMAT2,...